Study Title

A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy

Study Details

Description:

The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy.

Sponsor:

Abdera Therapeutics Inc.

Contacts:

Abdera Therapeutics

abderaclinicaltrials@abderatx.com

1 415 851 9503

Government Study Link:

NCT06736418 - Click here to see study on

ClinicalTrials.gov

Drug Details

111In-ABD147
Isotope(s):
    INDIUM-111
    Radioisotope: In-111
    Theranostic Role: SPECT Imaging
    T1/2 (Half-Life): 2.8 Days
    Decay Mode: ELECTRON CAPTURE, GAMMA
    Energy: 173 keV, 247 keV
    Range: N/A
    Decay Daughters: Cd111 (Stable)
    Status: FDA Approvals: ONCOSCINT® (1992), OCTREOSCAN® (1994)
  • INDIUM-111
Target(s):
  • DLL3

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468